Solid Biosciences Inc./$SLDB
1D1W1MYTD1Y5YMAX
Capital at risk
About Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
- Ticker
- $SLDB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 121
- Headquarters
- Charlestown, United States
- Website
- www.solidbio.com
SLDB Metrics
BasicAdvanced
$937M
-
-$1.87
2.42
-
Price and volume
Market cap
$937M
Beta
2.42
52-week high
$11.45
52-week low
$3.79
Average daily volume
850K
Financial strength
Current ratio
13.823
Quick ratio
13.213
Long term debt to equity
0.048
Total debt to equity
0.054
Profitability
EBITDA (TTM)
-210.524
Management effectiveness
Return on assets (TTM)
-36.38%
Return on equity (TTM)
-65.50%
Valuation
Price to book
2.46
Price to tangible book (TTM)
2.46
Price to free cash flow (TTM)
-5.155
Free cash flow yield (TTM)
-19.40%
Free cash flow per share (TTM)
-1.696
Growth
Earnings per share change (TTM)
-25.74%
3-year earnings per share growth (CAGR)
-32.93%
Upcoming events
No upcoming events
Funds containing SLDB
AllUSDGBPEUR
Fund name | Fund size | $SLDB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.